Jefferies Group LLC Supernus Pharmaceuticals, Inc. Call Options Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $3.96 Million - $5.13 Million	-150,000 Closed	0 $0
Q3 2021 Sep 21, 2023	BUY	$23.54 - $31.39 $882,750 - $1.18 Million	37,500 Added 33.33%	150,000 $4 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $882,750 - $1.18 Million	37,500 Added 33.33%	150,000 $4 Million
Q4 2020 Sep 21, 2023	BUY	$17.7 - $25.81 $1.99 Million - $2.9 Million	112,500 New	112,500 $2.83 Million
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $1.99 Million - $2.9 Million	112,500 New	112,500 $2.83 Million
Q4 2019 Feb 13, 2020	SELL	$19.93 - $29.13 $2.79 Million - $4.08 Million	-140,200 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$25.47 - $33.37 $45,846 - $60,065	1,800 Added 1.3%	140,200 $3.85 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $4.15 Million - $5.38 Million	138,400 New	138,400 $4.58 Million

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.06B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.